Xeris Biopharma Holdings, Inc. (XERS)
9.105
+0.16
(+1.73%)
USD |
NASDAQ |
Sep 25, 16:00
9.105
0.00 (0.00%)
After-Hours: 19:59
Xeris Biopharma Holdings Research and Development Expense (Annual) : 31.16M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 31.16M |
| December 31, 2024 | 25.56M |
| December 31, 2023 | 22.34M |
| December 31, 2022 | 20.97M |
| December 31, 2021 | 25.06M |
| Date | Value |
|---|---|
| December 31, 2020 | 19.92M |
| December 31, 2019 | 60.44M |
| December 31, 2018 | 40.65M |
| December 31, 2017 | 20.17M |
| December 31, 2016 | 10.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Zevra Therapeutics, Inc. | 12.55M |
| Aclaris Therapeutics, Inc. | 52.64M |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |
| Veru, Inc. | 15.59M |